Max's team line-up:

Oncology:
Dr. Ueno:
"...is currently the Director at the University of Hawaii Cancer Center,..."

Dr. Yam:
".. is an Associate Professor with dual appointments in the Departments of Breast Medical Oncology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. Dr. Yam is leader of the triple-negative breast cancer (TNBC) working group and Director of Team Science and Innovation in the Department of Breast Medical Oncology at MD Anderson.

Dr. J today on Dr. Pestell:
"...expertise will help CytoDyn maximize opportunities to pursue breakthrough treatment in a variety of cancer indications.”

MASH:
Dr. Palmer;
"...and explore new treatments that have the potential to truly transform patient outcomes.”

Everyone reports to Dr. Lataillade, who has zero hands-on, pre-clinical or clinical experience in any of the above indications.

I said if Dr. Pestell also reports directly to Cytodyn, then for me solidifies Max is GSK.

To each's own.